Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Anat AchironMathilda MandelSapir Dreyer-AlsterGil HarariDavid MagalashviliPolina SonisMark DolevShay MenascuShlomo FlechterRina FalbMichael GurevichPublished in: Therapeutic advances in neurological disorders (2021)